Tirzepatide (Mounjaro) 62% Diabetes Remission: SURPASS-REMIT Trial Results Explained

Diabetes Medications · 5 · March 8, 2026

Tirzepatide achieved 62% Type 2 diabetes remission in the SURPASS-REMIT trial. No drug has come close. Trial details, fine print, and who benefits most.